Rechercher des projets européens

Plus de 40 projets européens trouvés

Recherche sur 125080 projets européens

 EN COURS 
Many HIV vaccine concepts and several efficacy trials have been conducted in the prophylactic and therapeutic fields with limited success. There is an urgent need to develop better vaccines and tools predictive of immunogenicity and of correlates of protection at early stage of vaccine development to mitigate the risks of failure. To address these complex and challenging scientific issues, the Eur ...
Voir le projet

 43

 EN COURS 
As the number of older people in Europe grows, increasing healthy life years is a priority. Cognitive decline, dementia (e.g. Alzheimer’s disease, AD), sleep disturbances and depression, all related to psychological distress and anxiety, are significant drivers of reduced quality of life in older adults. This project builds on evidence that lifestyle factors and meditation practice have the potent ...
Voir le projet

 12

 EN COURS 
Arterial hypertension affects up to 45% of the general population and is responsible for 7.1 million deaths per year worldwide. Although a large therapeutic arsenal exists, blood pressure control is sub-optimal in up to two thirds of patients. Yet, even small increments in blood pressure are associated with increased cardiovascular risk, with 62% of cerebrovascular disease and 49% of ischemic hear ...
Voir le projet

 13

 EN COURS 
Parkinson’s disease (PD) is a major, chronic, non-communicable disease and the 2nd most frequent neurodegenerative disorder worldwide. Excess iron is primarily detected in the substantia nigra pars compacta, where dopaminergic neurons are exposed to high levels of oxidative stress produced by mitochondrial disorders and dopamine metabolism. Our previous preclinical, translational and pilot clinica ...
Voir le projet

 17

 TERMINÉ 
The overall aim of JPsustaiND is to support the development and extension of the capacities of the EU Joint Programming Initiative on Neurodegenerative Diseases, in particular Alzheimer's (JPND). Since 2009 JPND has been operating on a very light management structure based on a simple Terms of Reference. Through this JPND has been able to set a common Strategic Research Agenda, and to deliver its ...
Voir le projet

 16

 TERMINÉ 
"Type-1 diabetes (T1D) is an autoimmune disease in which pancreatic β-cells are gradually destroyed by autoreactive T-cells recognising autoantigens (Auto-Ag) such as GAD65 and insulin. ImCyse, a small SME, has developed a new technology based on short synthetic peptides flanked with a thioredox motif, which silence the pathogenic immune response against several auto-Ag through activation of one a ...
Voir le projet

 7

 TERMINÉ 

Heart OMics in AGEing (HOMAGE)

Date du début: 1 févr. 2013, Date de fin: 31 janv. 2019,

As more people survive into old age, the prevalence of heart failure (HF), one of the most common and debilitating diseases in older people, will rise still further. Delaying or preventing HF will have great benefit to those at personal risk, their families, society and the economy. HOMAGE aims to provide a biomarker (BM) approach that will a) help identify i. patients at high risk of developing ...
Voir le projet

 22

 TERMINÉ 

Metagenomics in Cardiometabolic Diseases (METACARDIS)

Date du début: 1 nov. 2012, Date de fin: 31 oct. 2018,

METACARDIS applies a systems medicine multilevel approach to identify biological relationships between gut microbiota, assessed by metagenomics, and host genome expression regulation, which will improve understanding and innovative care of cardiometabolic diseases (CMD) and their comorbidities. CMD comprise metabolic (obesity, diabetes) and heart diseases characterized by a chronic evolution in ag ...
Voir le projet

 18

 TERMINÉ 

Biomarkers of renal graft injuries in kidney allograft recipients (BIOMARGIN)

Date du début: 1 mars 2013, Date de fin: 28 févr. 2018,

In renal allograft recipients, 10-year graft survival has not improved over the past decades. Histological examination of graft biopsies has long been the gold standard to confirm graft injuries, but biopsies are invasive and histological grading is not very robust. There is thus a need for robust, non-invasive methods to predict and diagnose acute and chronic graft lesions, to improve patient tre ...
Voir le projet

 13

 TERMINÉ 
NanoAthero aims to have demonstration of initial clinical feasibility of nanosystems for targeted imaging and treatment of advanced atherosclerotic disease in humans. The nanosystems are assemblies of following components: nanocarrier, targeting, imaging agent/drug. They have proven safety records, and strong preliminary in vitro and in vivo proofs of efficacy are available. Partners have patented ...
Voir le projet

 17

 TERMINÉ 
RDEB is one of the most severe rare genetic skin diseases of children and adults characterized by skin blistering resulting from lack of expression of type VII collagen. There is no treatment for this life-threatening disease. In March 2009, we obtained the orphan drug designation for the Medicinal product: “Skin equivalent graft genetically corrected with a COL7A1-encoding SIN retroviral vecto ...
Voir le projet

 10

 TERMINÉ 
This project will tackle the huge complexity of taking stem cell therapies to clinical application for neurodegenerative disease by focusing on selective differentiation of a single neuronal phenotype (medium spiny striatal neuron: MSN) for a single well-defined disease (Huntington’s: HD). Our consortium contains expertise in all elements required to drive this technology to the point of clinical ...
Voir le projet

 10

 TERMINÉ 

Targeting cardiac fibrosis for heart failure treatment (FIBRO-TARGETS)

Date du début: 1 sept. 2013, Date de fin: 31 août 2017,

The Fibro-Targets project is a multi-disciplinary 4 years program involving 10 partners ambitioning “the identification, characterisation and validation of in vitro and in vivo models of novel therapeutically relevant targets” for myocardial interstitial fibrosis (MIF) in heart failure. The project is based on the hypothesis that the intervention on novel fibrosis-related targets involved in the p ...
Voir le projet

 11

 TERMINÉ 

European Research Infrastructure on Highly Pathogenic Agents 2 (ERINHA2)

Date du début: 1 janv. 2016, Date de fin: 30 juin 2017,

ERINHA2 aims to complete the work carried out during the first preparatory phase (PP1) - ERINHA - in order to reach the financial, administrative and technical maturity necessary to complete the establishment of the Research Infrastructre and ensure that the operation phase can begin in 2018. ERINHA2 will therefore finalise the decision to use the status of an association and prepare the necessary ...
Voir le projet

 17

 TERMINÉ 
Current approaches to improving glycaemic control in type 1 diabetes are centered on increasingly complex insulin delivery systems. However, less than 30% of patients can achieve target levels of glucose control with this approach even in a clinical trial setting and many patients are either unable or unwilling to make the personal commitment required. By contrast, preservation of even sma ...
Voir le projet

 8

 TERMINÉ 
The consortium led by UKER and EuroHYP, the European Stroke Research Network for Hypothermia, proposes a large, multicentre clinical trial which will assess mild hypothermia as a novel treatment for ischemic stroke.Stroke is the second cause of death world-wide and the second cause of lost disability-adjusted life years in high-income countries. Stroke incidence rises exponentially with age, so it ...
Voir le projet

 38

 TERMINÉ 

Anti-Parasitic Drug Discovery in Epigenetics (A-PARADDISE)

Date du début: 1 févr. 2014, Date de fin: 31 janv. 2017,

This proposal builds on the proven methodology developed in the SEtTReND FP7 project to develop inhibitors of schistosome HME as lead compounds for new drugs. We will employ a target-based strategy for the development of novel drug leads against schistosomiasis, leishmaniasis, Chagas disease and malaria by targeting histone modifying enzymes (HME), in particular those involved in acetylation/deace ...
Voir le projet

 16

 TERMINÉ 

What You Say Is What You Did (WYSIWYD)

Date du début: 1 janv. 2014, Date de fin: 31 déc. 2016,

The What You Say Is What You Did project (WYSIWYD) will create a new transparency in human robot interaction (HRI) by allowing robots to both understand their own actions and those of humans, and to interpret and communicate these in human compatible intentional terms expressed as a language-like communication channel we call WYSIWYD Robotese (WR). WYSIWYD will advance this critical communication ...
Voir le projet

 7

 TERMINÉ 

SYSTEMS BIOLOGY OF PATHWAYS INVOLVING BRAIN AGEING (AGEDBRAINSYSBIO)

Date du début: 1 janv. 2013, Date de fin: 31 déc. 2016,

In spite of valuable approaches applied to get a broad understanding of genetic, epidemiologic and molecular and system-level biological principles of human aging, cognitive decline remains as one of the greatest health challenges of the old age, with nearly 50% of adults over 85 afflicted of Alzheimer’s disease. Furthermore, drug development has not performed as expected in clinical trials, at le ...
Voir le projet

 15

 TERMINÉ 
Most cognitive functions are based on computations that take place in the cerebral cortex, composed of a larger number of areas, each with a complex anatomical structure, with neurons of different types and in different layers interacting according to a precise scheme. The anatomical organization of cortical areas is similar, with some modulation according to its sensory, motor or associative func ...
Voir le projet

 11

 TERMINÉ 
The therapeutic effect of the photodynamic therapy (PDT) depends on a combination of parameters that include drug dose, drug-light interval, oxygen in cells and light irradiance rate. It also varies according to the wavelength distribution of the light source. Finally, a homogeneous and reproducible illumination during the clinical PDT is determinant in preventing under- or overtreatment. So, the ...
Voir le projet

 12

 TERMINÉ 

The Human Brain Project (HBP)

Date du début: 1 oct. 2013, Date de fin: 30 sept. 2016,

Understanding the human brain is one of the greatest challenges facing 21st century science. If we can rise to the challenge, we can gain profound insights into what makes us human, develop new treatments for brain diseases and build revolutionary new computing technologies. Today, for the first time, modern ICT has brought these goals within sight. The goal of the Human Brain Project, part of the ...
Voir le projet

 116

 TERMINÉ 
Point-of-care (PoC) medical devices have the potential to revolutionise clinical practice. SMEs within our Consortium (Epistem & Biosurfit) have developed genetic and protein PoC devices to deliver on this promise. Results from these enabling technologies will be integrated using novel bioinformatics tools and algorithms (Qlucore) allowing for bed-side analysis. This integrated genetic-protein app ...
Voir le projet

 5

 TERMINÉ 
The richness of high-level cognitive and adaptive properties of the brain is reflected in the complexity of its anatomy and (electro)physiology. At the cellular level, evolution privileged for the central nervous system an analog distributed information storage and encoding, by plastic (graded) synapses and by their continuous temporal and spatial integration into firing rates. Beyond all-or-none ...
Voir le projet

 6

 TERMINÉ 
"The aim of TINN2 is to evaluate azithromycin, included in the EMEA priority list of the therapeutic areas that need specific drug evaluation in preterm and term neonates. Azithromycin is a macrolid antibiotic with anti-inflammatory properties active against Ureaplasma. It might be effective in reducing the severity of bronhopulmonary disease in which Ureaplasma infection and inflammation play a r ...
Voir le projet

 17

 TERMINÉ 

Stem Cells for Relevant Efficient Extended and Normalized Toxicology (SCR&TOX)

Date du début: 1 janv. 2011, Date de fin: 31 déc. 2015,

In the development of products for use by humans it is vital to identify compounds with toxic properties at an early stage of their development, to avoid spending time and resource on unsuitable and potentially unsafe candidate products. Human pluripotent stem cell lines offer a unique opportunity to develop a wide variety of human cell-based test systems because they may be expanded indefinitely ...
Voir le projet

 16

 TERMINÉ 

TRANSLATIONAL RESEARCH AND PATIENT SAFETY IN EUROPE (TRANSFoRm)

Date du début: 1 mars 2010, Date de fin: 30 nov. 2015,

TRANSFoRm will develop rigorous, generic methods for the integration of Primary Care clinical and research activities, to support patient safety and clinical research via:1.\tRich capture of clinical data, including symptoms and signs rather than just a single diagnosis. A generic, dynamic interface, integrated with electronic health records (EHR), will facilitate both diagnostic decision support ...
Voir le projet

 25

 TERMINÉ 
The aim of TINN is to evaluate ciprofloxacin, fluconazole and micafungin in neonates; two anti-infectious drugs included in the EMEA priority list of the therapeutic areas that need specific drug evaluation in preterm and term neonates. These drugs are prescribed off-label to treat neonatal infections that are life threatening situations and associated with long-term complications. In order to val ...
Voir le projet

 16

 TERMINÉ 
Multiple Myeloma (MM) is a currently incurable rare malignant plasma cell disease, which invariably relapses despite therapy. The objective of OVER-MYR is to understand the causes of drug resistance and relapse, develop novel strategies to overcome these, provide proof of principal for phase I/II trial, and thus impact on MM-patient’s survival.Currently-used drugs target both MM cells (MMC) and c ...
Voir le projet

 11

 TERMINÉ 

TriNeuron

Date du début: 31 janv. 2012, Date de fin: 29 juin 2015,

Neurex regroupe dans un cadre transfrontalier 110 laboratoires enneurosciences représentant plus de 1200 chercheurs mettant enoeuvre des approches et des techniques très variées. Les partenairesdu projet TriNeuron veulent créer au sein de leur réseau Neurex dansle Rhin supérieur, des actions et des interactions qui permettentd'assurer une recherche d'excellence, daccroître la compétitivité del'esp ...
Voir le projet

 9

 TERMINÉ 

Semantic Interoperability for Health Network (SemanticHealthNet)

Date du début: 1 déc. 2011, Date de fin: 31 mai 2015,

SemanticHealthNet will develop a scalable and sustainable pan-European organisational and governance process for the semantic interoperability of clinical and biomedical knowledge, to help ensure that EHR systems are optimised for patient care, public health and clinical research across healthcare systems and institutions.Through a clinically-driven workplan, exemplified in cardiovascular medicine ...
Voir le projet

 18

 TERMINÉ 

Mechanisms of the Development of ALLergy (MEDALL)

Date du début: 1 déc. 2010, Date de fin: 31 mai 2015,

Causes explaining the epidemic of IgE-associated (allergic) diseases are unclear. MeDALL (Mechanisms of the Development of Allergy) aims at generating novel knowledge on mechanisms of allergy initiation, in particular in childhood. To understand how a complex network of genetic and environmental factors leads to complex allergic phenotypes, a novel stepwise, large and integrative translational app ...
Voir le projet

 24

 TERMINÉ 
Pre-approval clinical trials cannot possibly ensure that a drug will not have disastrous side effects once it arrives on the market. Post-approval safety data gathering was put in place to address this problem, but as implemented, it has not proven to be as effective as hoped. This is due to the fact that, current post market safety studies largely depend on the submission of spontaneous case repo ...
Voir le projet

 10

 TERMINÉ 
As worldwide metabolic disease pandemics rise relentlessly with their concomitant clinical complications such as non alcoholic fatty liver disease, FLORINASH proposes an innovative research concept to address the role of intestinal microfloral activity in the pathogenesis of NAFLD. Firstly, to discover novel metabolic markers for the differential diagnosis and prediction of patient risk. Secondly, ...
Voir le projet

 6

 TERMINÉ 
Transplantation of donor hepatocytes has become an alternative to liver transplantation for the treatment of liver diseases. However, in addition to the complication imposed by severe shortage of donor livers, adult hepatocytes cannot be expanded in vitro. Autologous transplantation of genetically corrected hepatocytes represents another strategy as it circumvents the need for immunosuppression bu ...
Voir le projet

 7

 TERMINÉ 
... bio: Navarrabiomed-Fundación Miguel Servet (líder) ,Institute National de la Santé et de la Recherche Médicale (INSERM) de Midi Pyrénées Limousin,Instituto Aragonés de Ciencias de la Salud (IACS), Université Paul Sabatier de Toulouse, Centre Hospitalier Universitaire de Toulouse (CHU), Fundación Vasca de Innovación e Investigación Sanitarias (BIOEF), Centro de Investigación Biomédica de La Rioja ( ...
Voir le projet

 8

 TERMINÉ 

European Research Infrastructure on Highly Pathogenic Agents (ERINHA)

Date du début: 1 nov. 2010, Date de fin: 31 août 2014,

In the context of the emerging and re-emerging infectious diseases involving highly pathogenic microorganisms, European countries have to be well-prepared to face such threats. However, the Biosafety Level 4 (BSL4) capacity in Europe is not sufficient enough to cover the efficient development of diagnosis, prophylactic and therapeutics means against these pathogens. Moreover, there is no global co ...
Voir le projet

 27

 TERMINÉ 
The objective of the Coordination Action JUMPAHEAD is to support the implementation of the pilot Joint Programming Initiative on combating neurodegenerative diseases, in particular Alzheimer’s disease (JPND).Neurodegenerative disorders are incurable and debilitating conditions that result in progressive degeneration or death of nerve cells. Of these, the dementias are responsible for the greatest ...
Voir le projet

 13

 TERMINÉ 

Trans Channel Neuroscience Network (TC2N)

Date du début: 31 août 2009, Date de fin: 29 juin 2014,

The TC2N project is managed by a federation of 40 laboratories from Nijmegen to Brest, via Portsmouth called the LARC-Neuroscience Network. The project will focus on 5 main research topics: cerebrovascular accident (CVA), eating disorders, tumors, neurodevelopmental diseases and (neuro)endocrine disruptives.The main objectives of the project are: - to boost, widen and develop the LARC-Neuroscience ...
Voir le projet

 11

 TERMINÉ 
"Myasthenia Gravis (MG) is a heterogeneous rare autoimmune neurological disease affecting the neuromuscular junction (NMJ). The molecular events causing and maintaining MG are still unknown and current treatments do not lead to remission and entail considerable side-effects stressing the need for improved therapies. We will address the: 1. Natural course of disease: determine factors associated wi ...
Voir le projet

 13